We represented Pharos Capital Group in its acquisition of Horizon Oncology. The acquisition marks the launch of Verdi Oncology, Inc., an oncology practice and clinical research management company. Financial terms of the transaction were not publicly disclosed.

Horizon Oncology offers a wide range of comprehensive cancer services to patients, including advanced technological options, premier clinical expertise and cutting edge clinical trials opportunities, with a focus on early phase trials.

Pharos Capital Group is an SEC Registered Investment Advisor. As of March 2018, Pharos has invested in 51 companies and currently has over $690 million of private equity assets under management.